Biotechs are doing well recently, so I bought two this a.m.: Rosetta Genomics (ROSG @ 6.57) and Immunocellular Therapeutics (IMUC @ 3.04). ROSG has a very large short float while IMUC has a modest one. I have no idea how they are really doing as businesses and consider these purchases highly speculative. Hopefully these will get caught in a short squeeze some time in the future. Biotechs tend to self-destruct after I buy them, however.
Comments are closed.
